Linezolid anti MRSA Drug

Article Sidebar

PDF
Published: Jan 13, 2024
DOI: https://doi.org/10.47191/ijpbms/v4-i1-04

Main Article Content

Mohammad Jadaan Saad
(M.Sc. pharmacology), Pharmacology Department, faculty of Pharmacy, Anbar University, Anbar–Falloja,964, Iraq.
Sawsan Qahtan Taha Al-Quhli
(PhD Microbiology) College of Medicine/ Department of Medical Microbiology, University of Anbar
Teeb Ali Atea
(M.Sc. pharmacology), Hilla University College, Department of Dentistr

Abstract

One may argue that linezolid was the pioneer among the oxazolidinone antibiotics. This chemical is an antibiotic that has been synthesised. It binds to rRNA and stops bacteria from making proteins. Additionally, it slows down the pace of translation elongation reactions and prevents the formation of the initiation complex during protein synthesis, both of which shorten the produced peptide chains. A number of infections have been approved for treatment with linezolid, including those caused by vancomycin-resistant Enterococcus faecium, Staphylococcus aureus pneumoniae in hospitals, complicated SSSIs, uncomplicated SSSIs caused by methicillin-susceptible S. aureus or Streptococcus pyogenes, and Streptococcus pneumoniae in community settings.

Article Details

How to Cite
Saad, M. J. ., Sawsan Qahtan Taha Al-Quhli, & Teeb Ali Atea. (2024). Linezolid anti MRSA Drug. International Journal of Pharmaceutical and Bio Medical Science, 4(1), 27–29. https://doi.org/10.47191/ijpbms/v4-i1-04
Issue
Vol. 4 No. 1 (2024): Volume 04 Issue 01 January 2024
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Disord. 2001;1(2):181–199.

II. Hamel JC, Stapert D, Moerman JK, Ford CW. Linezolid, critical characteristics. Infection. 2000 Jan;28(1):60-4.

III. Batts DH. Linezolid-a new option for treating Gram-positive infections. Oncology. 2000;14(8 Suppl 6):23–29.

IV. Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. Am Fam Phys. 2002;65(4):663–670.

V. Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, Tarpley WG. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol. 2001;1:470–476.

VI. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159–168.

VII. Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect. 2006;12(4):391–394.

VIII. Karuppannasamy D, Raghuram A, Sundar D. Linezolid-induced optic neuropathy. Indian J Ophthalmol. 2014;62(4):497–500.

IX. Ishii N, Kinouchi R, Inoue M, Yoshida A. Linezolid-induced optic neuropathy with a rare pathological change in the inner retina. Int Ophthalmol. 2016;36(6):761–766.

X. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect. 2009;59(Suppl 1):S59–S74.

XI. Tessier JM, Puzio T, Young A, Wolfe L, Han J, Duane TM. Thrombo-cytopenia associated with linezolid therapy in solid organ transplant recipients: a retrospective cohort study. Surg Infect (Larchmt) 2015;16(4):361–367.

XII. Hsu SN, Shih MF, Yang CW, Wu CC, Chen CC. Severe linezolid-induced lactic acidosis in a cirrhosis patient. Nephrology (Carlton) 2015;20(1):47–48.

XIII. Kamal K, Dhasmana N, Kamble SS, Sahu RK. Linezolid induced adverse drug reactions – an update. Curr Drug Metab. 2015;16(7):553–559.

XIV. Viswanathan P, Iarikov D, Wassel R, Davidson A, Nambiar S. Hypoglycemia in patients treated with linezolid. Clin Infect Dis. 2014;59(8):e93–e95.

XV. Oh DH, Motorna O, Kong JB, Brown S, Gilbertson M. Linezolid-associated reticulocytopenia. Ann Hematol. 2016;95(12):2095–2097.